English
Ukuthuthukiswa kobuchwepheshe be-cell culture sekuvuthwe kakhulu kuze kube manje, futhi sekusetshenziswe kabanzi ekulungiseleleni amasosha omzimba e-monoclonal, ukukhiqizwa kokugoma, ucwaningo lwesayensi kanye neminye imikhakha. Isiko leseli lidinga usizo lwezinto ezisetshenziswa amaseli. Kunezinhlobo ezahlukene zezinto ezisetshenziswayo emakethe. Phakathi kwazo, i-cell factory iwuhlobo lokusebenziseka olunesakhiwo esikhethekile.
Ihlukile kwezinye izinto ezisetshenziswayo zohlobo lwamabhodlela, I-Cell Factory iyinto esebenzisekayo ekhethekile enesakhiwo esinezendlalelo eziningi. Ukucaciswa okuvamile kuhlanganisa ungqimba olu-1, izingqimba ezi-2, izingqimba ezingu-5, izingqimba ezingu-10, izingqimba ezingu-40, njll. Lapho uhlakulela amaseli, okuphakathi kuthululelwa ezingqimbeni zangaphakathi, futhi amaseli ahlanganiswe phansi ukuze akhule futhi ande. Ngenxa yenani eliphezulu le-10-layer kanye ne-40-layer layers, kunzima ukusebenza ngemva kokwengeza okuphakathi. Ngokuvamile, isetshenziswa kanye ne-shaker ezenzakalelayo. Ingakwazi ukubona ukuhlelwa, ukuzenzela kanye nokusebenza kahle kwesiko lamaseli amakhulu, ngaleyo ndlela kunciphise Kakhulu umfutho wabasebenzi kanye nokuminyana.
Ukusetshenziswa kwalesi sakhiwo esinezingqimba eziningi kunendawo enkulu yesiko, engonga isikhala, inciphise ukusebenza kwezandla, kanye nokunciphisa ingozi yokutheleleka. Ngokwendawo yesiko, indawo yesiko yefekthri yamaseli anezingqimba eziyi-10 ilingana namaflaski angamaseli angama-36 T-175. Izendlalelo zixhunywe inqubo ekhethekile yokushisela, engaqinisekisa ukuzinza kwendawo yangaphakathi futhi yakhe indawo enhle yokukhula ukuze amangqamuzana akhule. imikhakha ye-biopharmaceuticals kanye nocwaningo lwesayensi. Ngokuthuthuka okusheshayo kwemboni ye-biopharmaceutical, indawo yokukhula yesikhathi esizayo yalokhu okusebenzisekayo kufanelekile ukubheka phambili.
At present, cell factories have gradually replaced some traditional cell culture consumables and become mainstream consumables in the fields of biopharmaceuticals and scientific research. With the rapid development of the biopharmaceutical industry, the future growth space of this consumable is worth looking forward to.
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.